Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.41 |
| ▸ | ITGB2 | P05107 | 8/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 8/20 | 0.38 |
| ▸ | ITGAL | P20701 | 8/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924977 | 0.91 | TLR9 (0.41) | HRH3TLR9TLR8TLR7ITGB2 | |
| SCHEMBL6927128 | 0.90 | TLR9 (0.48) | HRH3TLR9TLR8TLR7TDO2 | |
| SCHEMBL6925239 | 0.89 | TLR9 (0.39) | HRH3TLR9TLR8TLR7ITGB2 | |
| SCHEMBL6926147 | 0.84 | HTR1A (0.41) | HRH3TLR9TLR8TLR7TDO2 | |
| SCHEMBL6925237 | 0.83 | WNT1 (0.42) | TLR9TLR8TLR7ITGB2ICAM1 | |
| SCHEMBL6925464 | 0.82 | DRD2 (0.44) | ITGB2ICAM1ITGALTDO2LRRK2 | |
| SCHEMBL6926804 | 0.81 | TRPA1 (0.39) | MAPK14 | |
| SCHEMBL6925249 | 0.80 | ITGB2 (0.49) | ITGB2ICAM1ITGALTDO2 | |
| SCHEMBL6927297 | 0.80 | DRD2 (0.43) | ITGB2ICAM1ITGAL | |
| SCHEMBL6925647 | 0.78 | TLR9 (0.45) | HRH3TLR9TLR8TLR7LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514966-B2 | Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine | PFIZER INC. | 2003-02-04 | — | — | US | disclosed |
| US-6355635-B1 | IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY | PFIZER INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039277-A1 | Compounds for the treatment of obesity | NPY1R, NPY4R, NPY2R | HRH3 816/4885TLR9 3876/4885TLR8 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.